ProCAncer-I at the Clinical and Translational Oncology Conference 2022 in Heraklion

Published on: November 20, 2022
Categories: News

The ProCAncer-I project participated at the Clinical and Translational Oncology Conference 2022 organised by the Department of Medical Oncology of the University General Hospital of Heraklion (PAGNI) which was held on November 17-20, 2022 in Heraklion, Crete, at the Atlantis Hotel.

During the Conference, the latest developments in Oncology were presented, with a special view on the innovations being introduced into clinical medical practice. The aim is to integrate these innovations into the everyday medical practice, and increase the effectiveness of treatment while protecting the patients’ quality of life.

ProCAncer-I team participated at the session “Digital Transformation in Healthcare”, coordinated by K. Marias, N. Tavernarakis and D. Mavroudis, with Prof Fotiadis who talked about the technological transformation of Health in 2022, and Prof. Tsiknakis who delivered a speech concerning the “Regulatory approval of artificial intelligence models for clinical use: current challenges and opportunities”

 

Highlights

ProCAncer-I at the EMUC24 in Lisbon

ProCAncer-I at the EMUC24 in Lisbon

The progress of major trials, the advent of artificial intelligence (AI), and interdisciplinary best practices will comprise the scientific programme of the 16th European Multidisciplinary Congress on Urological Cancers (EMUC24), which will take place from 7 to 10...

Third Dissemination Event of the ProCAncer-I Project in Athens

Third Dissemination Event of the ProCAncer-I Project in Athens

ProCAncer-I organised the 3rd Dissemination Event of the project at the 21st IEEE International Symposium on Biomedical Imaging, held in Athens, Greece, May 27-30, 2024. During the symposium, ProCAncer-I organised the Workshop “Integrating imaging Data and AI models...

AI in PCa imaging : The current status and future perspectives

AI in PCa imaging : The current status and future perspectives

Ιn recent years, magnetic resonance imaging (MRI) has transformed the prostate cancer (PCa) diagnostic pathway, based on the evidence of multiple high-level evidence studies (refs 4M, MRI first, and PROMIS). Taken together, the evidence indicates that prostate MRI...

Open Call To Include New Beneficiaries Into The EUCAIM Consortium

Open Call To Include New Beneficiaries Into The EUCAIM Consortium

The EUCAIM project is launching an open call for new beneficiaries to join the consortium. The objective of the EUCAIM open call is to: i) onboard new cancer image data holders, increasing the geographic dimensions, data modalities or cancer targets, and  ii) include...

Stay in touch!